Trodelvy (sacituzumab govitecan-hziy) is the first and the only approved antibody-drug conjugate for the treatment of advanced triple-negative breast cancer (TNBC) in adult patients.
11 May 2020 projects
7 May 2020 News
Innovent Biologics and Eli Lilly and Company have reported positive results from the ORIENT-12 Phase III trial of TYVYT, Gemzar and platinum chemotherapy combination in metastatic squamous non-small cell lung...
1 May 2020 projects
Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.
24 April 2020 projects
TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.
17 April 2020 projects
Koselugo® (selumetinib) is the first FDA-approved drug indicated for the treatment of neurofibromatosis type 1 (NFI), a rare and incurable genetic condition, developed and commercialised globally by AstraZeneca and Merck (MSD)...
9 April 2020 projects
Sarclisa® (isatuximab-irfc) is a monoclonal antibody in combination with pomalidomide and dexamethasone (pom-dex) indicated for the treatment of multiple myeloma.
7 April 2020 News
Biopharmaceutical company Immunomedics has stopped the confirmatory Phase III ASCENT clinical trial of sacituzumab govitecan early after obtaining encouraging efficacy data in metastatic triple-negative breast cancer (mTNBC) patients.
24 March 2020 News
AbbVie has reported positive results from the Phase III VIALE-A clinical trial of Venclexta (venetoclax) plus azacitidine in treatment-naïve acute myeloid leukaemia (AML) patients who cannot receive intensive chemotherapy.
16 March 2020 News
WPD Pharmaceuticals has reported positive data from the Phase I clinical trial of Berubicin drug to treat glioblastoma multiforme (GBM).
11 March 2020 News
Cancer care specialist community Tennessee Oncology has joined Targeted Oncology’s strategic alliance partnership (SAP) programme.